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Introduction
The inability to attain or maintain a penile erection sufficient 
for sexual intercourse is a common problem experienced by a 
third of men over the age of 40 years.1 Erectile dysfunction (ED) 
is a debilitating disease which can have profound psychological 
effects on personal relationships and the social well-being of 
the affected individual. The diagnosis and evaluation of sexual 
dysfunction has been well described, and several validated 
algorithms are available to quantify the classification and severity. 
The International Index of Erectile Function (IIEF) and the Sexual 
Health Inventory for Men questionnaires are commonly used in 
the initial assessment of ED.2 
Several risk factors have been linked to the pathophysiology 
of ED. Endothelial damage has been the focus of many recent 
studies. An evaluation of the cardiovascular status, in addition 
to the administration of questionnaires to men with ED, might 
reduce mortality and improve sexual quality of life.3 
The mechanism of an erection
Penile tumescence and detumescence depend on the complex 
integration of various neurovascular signalling pathways. 
This includes autonomic neurotransmitters (noradrenalin and 
serotonin), nonadrenergic, noncholinergic neurotransmitters 
(neural nitric oxide and vasoactive intestinal polypeptide), 
and vasoactive agents produced by the vascular endothelium 
(prostacyclin and prostaglandin).
Tumescence
Sexual stimulation results in nitric oxide (NO) being released 
from the nerve endings in the corpus cavernosum. In turn, NO 
mediates the release of cyclic guanosine monophosphate 
(cGMP) via the activation of the enzyme, guanylate cyclase. cGMP 
triggers smooth muscle relaxation, allowing increased arterial 
inflow and filling of the sinusoids in the corpus cavernosum. The 
accumulation of blood increases the intracavernosal pressure, 
causing passive veno-occlusion and subsequent erection. 
Continuous smooth muscle relaxation and a sustainable 
erection is dependent on cGMP, including the release of NO, 
and prostaglandins and prostacyclins from the endothelium 
in response to the mechanical stretching caused by the initial 
increase in pressure.4 
Detumescence
Detumescence occurs when cGMP is degraded to the inactive 
form via specific hydrolysing phosphodiesterase-5 (PDE-5) 
enzyme, almost exclusively present in the corpus cavernosum. 
Ejaculation is mediated by the action of noradrenalin on the 
α1-adrenoreceptors, followed by contraction of the vascular 
and trabecular smooth muscle. The intracavernosal pressure 
decreases and the veno-occlusion terminates. This physiological 
effect of smooth muscle contraction after ejaculation results in 
a refractory period whereby immediate restimulation does not 
result in subsequent vasodilation and arterial filling.
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The effect of serotonin on erectile function involves sympathetic, 
parasympathetic and somatic outflow mechanisms, and is 
considered to exert a general inhibitory effect on male sexual 
behaviour.5 
Causes of erectile dysfunction
As with most diseases, ED can be attributed to organic (physical) 
and non-organic (psychological) causes, but is often the result 
of a combination of both.6 Traditionally, physical causes refer 
to vasculogenic, neurogenic or endocrinological disorders 
(Table I) and should be differentiated from other male sexual 
dysfunctions, such as premature ejaculation, Peyronie’s disease 
(anatomical causes) and disorders of orgasm. The absence of 
morning erections, muscle pain and cramps relieved by rest and 
numbness in the saddle area might indicate a physical cause and 
should be thoroughly investigated.  
Psychogenic causes are mostly the result of depression, low self-
image, relationship conflict and a stressful lifestyle, which, in turn, 
lead to performance anxiety and a reduction in the desire to be 
intimate. ED is known to be associated with certain drugs7 (Table 
II). Identifying the cause and assessing the risk factors may be 
beneficial in reducing the mortality as a result of other medical 
conditions, and in particular, cardiovascular disease, where 
endothelial cell damage is the first event  in the atherosclerotic 
process.3,8 The famous phrase “ED equals endothelial damage, 
which equals early death” is taught to medical students around 
the world in an attempt to emphasise the importance of 
reducing cardiovascular risk factors, which might start off by an 
undiagnosed patient presenting with ED.
Treatment options
Several treatment options for ED are available. They consist 
of mechanical devices (vacuum pumps and constriction 
rings), surgical interventions (prosthetic penile implants, 
arterial reconstruction and venous blocking procedures), 
and pharmacological management (PDE-5 inhibitors, 
testosterone replacement therapy and invasive prostaglandin 
administration).9 The current approach to management aims to 
identify the underlying cause. Lifestyle interventions and limiting 
cardiovascular risk factors, such as smoking, hypertension, 
dyslipidaemia and obesity, should be advocated. Psychotherapy 
alone, or in combination with psychoactive drugs and PDE-5 
inhibitors, should be prescribed when depression or anxiety 
is the primary cause.10 When a selective serotonin reuptake 
inhibitor is implicated as a possible cause, the appropriate 
addition of buproprion could be considered.11  
First-line medical therapy with a PDE-5 inhibitor is recommended 
because of its efficacy, favourable side-effect profile and ease of 
use. Men with low serum testosterone levels should additionally 
receive hormonal replacement therapy, unless there are 
contraindications.12 Second-line treatment is reserved for men 
who do not respond to PDE-5 inhibitors. Available options 
include noninvasive vacuum devices and invasive alprostadil 
administration (intracavernosal injection or intraurethral 
suppository).13 Surgical interventions, such as prosthetic penile 
implantations and revascularisation procedures, are mainly 
reserved for failed first- and second-line responses.14 
Phosphodiesterase-5 inhibitors 
Currently, there are four available registered PDE-5 inhibitors, i.e. 
sildenafil, vardenafil, tadalafil and avanafil. The latter was only 
approved for registration and prescription in the USA from 2012, 
and in Europe, Australia and New Zeanland from 2013. South 
African registration was still pending at the time of submission 
of this article.
PDE-5 inhibitors share a similar mechanism of action and general 
side-effect profile. However, individual agents have distinct 
pharmacokinetic and pharmacodynamic properties, which 
facilitate the tailoring of sexual therapy according to patients’ 
needs.15 These agents do not cause tumescence in the absence 
Table I: Organic causes associated with erectile dysfunction












• Spinal cord injury
• Pelvic surgery
• Testosterone deficiency syndrome 
• Hypogonadism
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GnRH: gonadotropin-releasing hormone, SSRIs: selective serotonin reuptake inhibitors, TCAs: tricyclic antidepressants
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of sufficient sexual arousal and stimulation, but cause a marked 
reduction in the post-ejaculatory refractory time. However, a 
decrease in detumescence is achieved by inhibiting the PDE-
5 enzyme, thereby effectively increasing the intracavernosal 
cGMP responsible for NO-induced smooth muscle relaxation 
and expansion in blood flow. The result is an increase in the 
number, strength and duration of erections. PDE-5 inhibitors are 
contraindicated in men receiving nitrate therapy, and should be 
used cautiously in combination with alpha-adrenergic blockers 
because of the risk of life-threatening hypotension. Common 
side-effects include headaches, flushing, dyspepsia and nasal 
congestion.16 In general, PDE-5 inhibitors appears to be safe in 
men > 65 years of age, although not specifically indicated as 
such.
Sildenafil
Sildenafil is the prototype PDE-5 inhibitor, and remains effective 
in treating mild ED, or men who do not complain of ED, but 
display risk factors and low IIEF scores, including ED-associated 
with Parkinson’s disease.11 
Vardenafil
Vardenafil is comparable to sildenafil, but more effective in 
treating ED associated with diabetes or nerve-sparing radical 
prostatectomy. Orally disintegrating tablet formulations have a 
more rapid onset of action and higher systemic exposure than 
conventional film-coated tablets. Vardenafil is not influenced by 
the presence of food, making it preferable in some patients who 
require an immediate effect.17 
Tadalafil
Tadalafil has the same efficacy as that of sildenafil and vardenafil, 
but a much longer duration of action. Lower doses can be used 
daily, but it still appears to be less effective than high-dose, on-
demand administration.3 
Table III: A comparative summary of currently available phosphodiesterase-5 inhibitors
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ODT: orally disintegrating tablet, SEP: single exit price 
*Single exit price, as listed in the Monthly Index of Medical Specialities. 2015;55(4)
**Not available in South Africa
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Avanafil
Avanafil is the newest PDE-5 inhibitor. It exhibits enhanced PDE-
5 selectivity compared to the other available PDE-5 inhibitors, 
thereby displaying a more favourable side-effect profile. It has a 
rapid onset of action, and is the only PDE-5 inhibitor specifically 
indicated for ED in men > 65years of age.18
Table III provides a comparative summary of currently available 
PDE-5 inhibitors.
Testosterone replacement therapy
Administering testosterone in the absence of low testosterone 
levels may be ineffective in treating ED and increases the risk of 
hepatic and prostate cancer. Testosterone replacement therapy 
should only be initiated in men with serum testosterone levels 
≤ 12 nmol/l, indicative of testosterone deficiency syndrome.19 
Low levels of testosterone in the presence of raised prolactin, 
abnormal follicle-stimulating hormone or luteinising hormone, 
thyroid-stimulating hormone, thyroxine  and cortisol should be 
evaluated by an endocrinologist for specialist care.
There is a strong association between metabolic syndrome and 
testosterone deficiency syndrome.4 This necessitates the routine 
evaluation of testosterone levels in all patients with features 
of cardiovascular disease and diabetes mellitus, regardless 
of the presence or absence of ED.20 Long-acting testosterone 
undecanoate 1 000 mg [Nebido®, Bayer HealthCare, single exit 
price (SEP) of R1 636.09 for 1 000 mg] may be injected 4-5 times 
per year, and shows a significant improvement in libido, morning 
erections, mood changes and depressive symptoms. Shorter-
acting testosterone cypionate 200-400 mg (Depo-Testosterone®, 
Pfizer, SEP of R337.29 for 1 000 mg) can be injected every 
3-4 weeks in patients where cost is an issue, but does not provide 
the favourable physiological profile associated with the long-
acting agent.
Intracavernosal prostaglandin injections
Alprostadil (Caverject®, Pfizer, SEP of R166.17 for 20 µg) is 
indicated as the second-line treatment when PDE-5 inhibitors 
fail, or patients experience an unsatisfactory response.7 Failure 
is regarded as the inability to attain or maintain an adequate 
erection on at least four successive occasions while on optimal 
PDE-5 inhibitor drug dosing. Alprostadil may be preferred in men 
with spinal cord injuries or post radical prostatectomy. 
The intracavernosal injection of alprostadil blocks the inhibitory 
effect of the sympathetic nervous system, and acts as a direct 
smooth muscle vasodilator, causing an increase in blood flow to 
the penis. A predictable, sustainable erection is achieved within 
10 minutes, and is independent of sexual stimulation. Compliance 
is the largest indicator for discontinuation, and patients need 
adequate counselling before commencing treatment. Side-
effects include pain at the site of injection, hypotension and 
priapism, and penile fibrosis, if not administered correctly.   
Conclusion
ED is a common condition and is vastly undertreated. Healthcare 
providers need to be familiar with all of the currently available 
treatment options. Association with an increased risk of 
cardiovascular disease and mortality should make physicians 
more vigilant and proactive with regard to the management 
of ED. Serum testosterone levels should be regularly checked 
in men with features of metabolic syndrome and ED. Stigma 
around the condition should be eliminated by proper education. 
Patients should be encouraged to report any symptoms to 
their healthcare provider, including primary care workers and 
pharmacists, who are in a position to adequately refer them to 
a physician. Mass media campaigns and government initiatives 
may improve cardiovascular mortality by creating public 
awareness concerning the health risks associated with ED. 
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